drugset / Trial / NCT01928459
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.
Timeline
- Start
- 2013-10
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | — | Oral |
| Subject | Infigratinib | Small molecule | — | Oral |